

The global [mycoplasma testing market](#) is projected to grow from \$972.3 million in 2025 to \$1.39 billion by 2032, with a 5.3% CAGR. North America dominates with a 49.02% market share, driven by research activities and R&D investments.

Key highlights:

- Mycoplasma contamination affects 15-35% of continuous cell cultures globally
- Reagents & kits segment leads the market due to high usage in research labs
- PCR-based testing methods hold the largest share due to high sensitivity
- Biopharmaceutical companies are the primary end-users
- COVID-19 positively impacted the market through increased vaccine development testing

Market constraints include high testing costs and a shortage of trained professionals, particularly affecting adoption in emerging markets.

Recent developments show industry consolidation, with SD Biosensor acquiring Meridian Bioscience in January 2023, and significant investments like Pfizer's \$100 million research partnership with Flagship Pioneering in July 2023.

Report-

[Fortune Business Insights - Mycoplasma Testing Market Size, Share | Growth Report \[2032\]](#)

<https://www.fortunebusinessinsights.com/mycoplasma-testing-market-108687>